Repligen Corporation (RGEN) Stock: Price, Forecast & Analyst Target
Repligen Corporation (RGEN) — MoonshotScore 71/100 (Strong band), calculated Nov 18, 2026. Price $170.29 (-1.38%), as of the Nov 19, 2026 trading session; market cap $10.9B. Expected results Feb 23, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 12.63× (cash as of Sep 30, 2026) · expected results Feb 23, 2027
Repligen Corporation · RGEN · NASDAQ · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered): Repligen supplies the filtration, chromatography, protein and process-analytics tools used to develop and manufacture biological drugs; it is an enabling-technology vendor, not a drug developer. Its case depends on whether rising demand, particularly for OPUS chromatography products, can outpace the operating costs accompanying that growth.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Repligen (RGEN)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a strong balance sheet, but an expensive valuation; the market is already moving on it. Business Quality: Solid; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $209M (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 7 of the last 8 reports
- Altman Z 8.43 · Piotroski F 4
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 74 | Strong | |
| 74 | Strong | |
| 74 | Strong | |
| 74 | Strong | |
| 71 | Strong | |
| 71 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $170.29 | |
| Change on the day | -1.38% | |
| 52-week range | $100.99–$198.87 | |
| Market capitalisation | $10.9B | — |
| Price / earnings (trailing) | 243.47 | |
| Shares traded on the day | 880.6K | |
| Beta (volatility vs the S&P 500) | 1.12 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We expect CapEx spend to continue to be approximately 3% to 4% of 2026 revenue.
Jason K. Garland · Statement from
For additional context, at the midpoint, our guidance assumes fourth quarter organic growth is in the range of our updated full year outlook.
Jason K. Garland · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Repligen (RGEN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 14, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Repligen (RGEN), and what does it report?
Short answer · as of
Repligen sells bioprocessing components and integrated systems to biopharmaceutical companies, contract manufacturers, diagnostics businesses and laboratory researchers.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Its portfolio spans upstream cell-culture processing, downstream concentration and purification, affinity ligands, prepacked chromatography columns and in-process measurement systems.
Reported revenue overwhelmingly represents product sales. Filtration is the largest disclosed product family, followed by chromatography, while proteins and process analytics provide additional exposure to biologics production workflows.
What do the latest results show for Repligen (RGEN)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $209M.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Revenue extended an uninterrupted sequential rise and reached the highest level in the reported quarterly series. Gross profit also reached a series high, yet operating profit, net income and diluted earnings weakened again as selling and administrative expense remained elevated.
Management had linked its stronger chromatography outlook to OPUS traction and anticipated a richer chromatography mix, while also flagging additional investment. The latest accounts therefore show improving sales and gross economics without corresponding operating leverage, even as reported revenue and adjusted earnings again exceeded expectations.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $209.31M Sep 30, 2026
- Latest quarter · R&D
- $14.44M Sep 30, 2026
- Latest quarter · SG&A
- $83.59M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$29.55M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $209.31M | $14.44M | $83.59M | −$29.55M |
| Jun 30, 2026 | $204.13M | $14.42M | $76.62M | $11.93M |
| Mar 31, 2026 | $194.25M | $14.46M | $76.54M | $17.99M |
| Dec 31, 2025 | $197.91M | $12.18M | $62.70M | $18.56M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $209.31M Oct 27, 2026
- Latest report · revenue estimate
- $206.70M Oct 27, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 27, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 27, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 27, 2026 | $209.31M | $206.70M | $0.5300 | $0.4628 |
| Jul 28, 2026 | $204.13M | $201.59M | $0.5400 | $0.4470 |
| May 5, 2026 | $194.25M | $192.05M | $0.4800 | $0.3800 |
| Feb 24, 2026 | $197.91M | $192.94M | $0.4900 | $0.4400 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $209M | -$38M | -$0.68 (diluted) |
| Q2 FY2026 | $204M | $5M | $0.09 (diluted) |
| Q1 FY2026 | $194M | $8M | $0.15 (diluted) |
| Q4 FY2025 | $198M | $13M | $0.23 (diluted) |
What are the financial strengths and risks for Repligen (RGEN)?
Short answer · as of
Cash and short-term investments were $862.98M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $43.10M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Cash and short-term investments exceed total debt, leaving Repligen in a net-cash position. Liquidity has risen across recent reporting periods, operating cash flow has remained positive throughout the available quarterly series, and capital spending has consumed only a modest share of that inflow.
The financial tension lies between balance-sheet resilience and modest current returns. Trailing margins and returns on capital remain subdued, while earnings and free-cash-flow yields are thin relative to the market value; failure to convert OPUS and broader bioprocessing demand into operating leverage would therefore expose the valuation.
Data-derived red flags
- Negative return on equity (-0.6%) — the business is not currently generating profit on shareholder capital.
- Rich valuation — a P/E of 243.47 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $43.10M Sep 30, 2026
- Previous quarter · operating cash flow
- $32.77M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $43.10M | −$4.95M |
| Jun 30, 2026 | $32.77M | −$5.10M |
| Mar 31, 2026 | $28.30M | −$4.95M |
| Dec 31, 2025 | $25.70M | −$8.66M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Repligen (RGEN)?
Short answer · as of
The next earnings report is expected on Feb 23, 2027.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
The scheduled earnings release should be tested against consensus expectations for another top-line advance but softer adjusted earnings. More important than another estimate beat is whether operating profit stabilizes while revenue continues rising.
OPUS demand, chromatography growth and the resulting product mix are the company-specific operating signals to follow. Cash conversion should corroborate any improvement: continued positive operating cash flow, restrained capital spending and further liquidity accumulation would show that growth is financing itself.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
This also means we will deliver a gain on our full year commitments and outpacing markets significantly.
Olivier Loeillot ·
Given recent trends, we plan to make some investments through the end of this year to support our expected growth in 2027. We will remain thoughtful about balancing investments in the business and expanding margins.
Jason K. Garland ·
How does Repligen compare with its peers?
Short answer
Repligen's score ranks tied for 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Repligen differs from a drug developer because it does not rely on the clinical success of a single therapeutic molecule. It sells tools consumed or deployed across customers’ process development and biological manufacturing operations.
Its breadth also distinguishes it from a narrowly focused laboratory-equipment supplier: filtration reaches upstream and downstream workflows, chromatography addresses purification, proteins supply affinity inputs, and process analytics measures production behavior. That breadth spreads demand across workflow steps, but filtration remains the largest disclosed product family and OPUS makes chromatography especially important to the present growth narrative.
| Company | Price | Market value | Score |
|---|---|---|---|
| $70.53 Nov 18, 2026 | $9.34B | 94 5-pillar Nov 18, 2026 | |
| $404.02 Nov 18, 2026 | $28.1B | 92 5-pillar Nov 18, 2026 | |
| $120.37 Nov 19, 2026 | $5.48B | 83 5-pillar Nov 18, 2026 | |
| $84.41 Nov 19, 2026 | $5.06B | 81 5-pillar Nov 18, 2026 | |
| $140.34 Nov 19, 2026 | $8.90B | 77 5-pillar Nov 18, 2026 | |
| $156.24 Nov 19, 2026 | $9.83B | 76 5-pillar Nov 18, 2026 | |
| $175.76 Nov 19, 2026 | $4.40B | 73 5-pillar Nov 18, 2026 | |
| $15.93 Nov 19, 2026 | $4.35B | 73 5-pillar Nov 18, 2026 | |
| Repligen (RGEN) — this page | $170.29 | $10.9B | 71 |
| $15.12 Nov 19, 2026 | $10.3B | 71 5-pillar Nov 18, 2026 | |
| $327.93 Nov 19, 2026 | $15.7B | 70 5-pillar Nov 18, 2026 | |
| $163.40 Nov 19, 2026 | $6.48B | 61 5-pillar Nov 18, 2026 | |
| $25.39 Nov 19, 2026 | $13.1B | 57 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $160.00 – $225.00
- Consensus target
- $198.00
- Median target
- $200.00
Consensus record · Captured .
Measured against a quoted price of $170.29 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 6, 2026
- Transactions
- 24
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 8
- Other transactions
- 16
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 535 Period end Sep 30, 2026
- Previous quarter · holders
- 500 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 7,350,873 |
| Blackrock, INC. | 5,726,731 |
| United Capital Financial Advisors, LLC | 2,790,038 |
| Vanguard Capital Management LLC | 2,442,741 |
| Vanguard Portfolio Management LLC | 2,271,873 |
Tracked investors
Which of the 16 named investors we follow held RGEN in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0.33% | $14.88M | Held, unchanged |
| Viking Global | Andreas Halvorsen | Q3 2026 | 0.31% | $102.12M | New position |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.07% | $17.13M | New position |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Repligen (RGEN)?
Common Questions About RGEN (Healthcare)
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does OPUS matter to Repligen?
OPUS comprises prepacked chromatography columns used in biologics purification and smaller formats used for process development and validation. Management cited OPUS traction when raising its chromatography outlook, making adoption of the platform a direct test of the current growth narrative.
Is Repligen a biologic drug developer?
Repligen supplies the manufacturing and process-development tools used by biologic drug producers. Its sales depend on customer activity across cell culture, filtration, purification and process analysis rather than approval of a Repligen-owned medicine.
Why is filtration important to Repligen?
Filtration is Repligen’s largest disclosed product family and spans upstream perfusion, downstream concentration, formulation, dialysis and single-use flow paths. This gives the company exposure to several stages of biological manufacturing rather than a single laboratory task.
Can Repligen finance its bioprocessing investment from operations?
Operating cash flow has remained positive across the available quarterly series and comfortably exceeded capital spending. Cash and short-term investments have also continued rising, indicating that recent investment has not eroded the liquidity cushion.
What is the RGEN stock price today?
The last price recorded for Repligen Corporation (RGEN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RGEN price target?
The analyst consensus price target for Repligen Corporation (RGEN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 81 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com